
Shares of Nvidia Corp. rose 0.4% in the early premarket session on Tuesday, amid a bullish signal regarding its China business.
The AI chipmaking giant refuted an earlier report claiming it was asking Chinese customers for complete upfront payments for its H200 chips, even as regulatory issues have kept those sales on pause.
In a response to Reuters, which broke the story, an Nvidia spokesperson said the company “would never require customers to pay for products they do not receive."
On Stocktwits, retail investors view Nvidia’s clarification as a positive signal, fueling speculation that Beijing is close to re-allowing H200 sales. In recent weeks, reports have emerged forecasting China’s imminent approval, while Nvidia’s management told analysts at the CES trade show that Chinese demand for its chips remained strong despite uncertainties.
“Making H200 chips easier to grab = massive U.S. sales to China + global AI dominance. Let's go!” a user commented.
Retail sentiment for NVDA, however, climbed a few notches lower in the ‘bullish’ zone as of early Tuesday, as compared to the previous day.
Nvidia’s sales in China have now been upset for years amid U.S.-China diplomatic and trade tensions. The Biden administration had banned the export of advanced AI chips to China, but President Donald Trump reversed that policy last month, allowing H200 sales with a 25% fee paid to the U.S. government.
Previously, Nvidia had to write down $5.5 billion in inventory after the Trump administration expanded the ban to include Nvidia’s H200 chip, the most powerful processor the company was previously allowed to sell in China.
The China holdup remains a major issue for Nvidia investors; pending a clear or official signal, the stock has declined about 11.3% since its lifetime high of $206.88 on Nov. 3.
In other news, Nvidia on Monday announced a collaboration with drug giant Eli Lilly for a new AI lab for advanced drug development. It also announced a collaboration with the life sciences tools company Thermo Fisher and launched new models in its BioNeMo program, an open development platform for AI-driven biology and drug discovery projects.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.